Combination Therapy Using Durvalumab and Histotripsy for Treatment of Intrahepatic Cholangiocarcinoma

The purpose of this research is to evaluate whether adding histotripsy to maintenance durvalumab increases immune response and to assess the safety of this combination for participants with advanced intrahepatic cholangiocarcinoma (iCCA). Histotripsy is a non-invasive, non-thermal treatment that uses focused ultrasound energy to destroy tumor tissue. 12 people will be enrolled in this study.

NCT Number	NCT07766187
Lead Sponsor	University of Wisconsin, Madison Collaborators: HistoSonics, Inc.
Conditions	Intrahepatic Cholangiocarcinoma
Enrollment	12 participants
Start Date	2026-08
Primary Completion	2032-08 (estimated)
Study Completion	2032-08 (estimated)
Updated on ClinicalTrials.gov	2026-08-14